Anti-diabetic effects of excipients: Possibility of formulation of an anti-diabetic dosage form using pharmaceutical excipients or their constituents, or food additives

Journal of Excipients and Food Chemicals

Volumn 1, Issue 1, 2010, Pages 2-10

  Apte, Shireesh Prakash ^a  

^a Alcon Research Inc   (United States)

Author keywords

Bioactive; Diabetes; Dietary supplement; Excipient; Food additive; Promiscuous

Indexed keywords

ACETIC ACID; ACUROX; ALPHA TOCOPHEROL; ALTEPLASE; ARGININE; ATENOLOL; CHIROINOSITOL; CYCLIC GMP; DOCOSAHEXAENOIC ACID; FATTY ACID; FOOD ADDITIVE; GLUCOSE; GUAR GUM; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INOSITOL DERIVATIVE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; MAGNESIUM CARBONATE; MAGNESIUM CHLORIDE; MAGNESIUM STEARATE; NICOTINIC ACID; NITRIC OXIDE; OCTANOIC ACID; OXYCODONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; THIOCTIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; WATER;

ARTICLE; DAIRY PRODUCT; DIABETES CONTROL; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG PACKAGING; ENZYME ACTIVITY; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; FOOD COMPOSITION; GLUCOGENESIS; GLUCOSE ABSORPTION; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOLYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL REQUIREMENT; POSTPRANDIAL STATE; POWDER; STOMACH EMPTYING; VASODILATATION;

EID: 79952077588     PISSN: None     EISSN: 21502668     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Marina AM, CheMan TB, Amin I. Virgin coconut oil: emerging functional food oil. Trends in Food Sci. and Technol., 20(10): 481-487, 2009.
2. Piatti P, Federica M, Monti L, Galli-Kienle M, Valsecchi G, Pozza G, et.al. Long-Term oral l-Argining administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. Diabetes Care, 5: 875-880, 2001.
3. Petrie JR, Ueda S, Webb DJ, Elliot HL, Connell GMC. Endothelial NO production and insulin sensitivity; a physiological link with implications for pathogenesis of cardiovascular disease. Circulation, 93: 1331-1333, 1996.
4. Balon TW, Nadler JL. Evidence that nitric oxide increases glucose transport in skeletal muscle. J. Appl. Physiol, 82: 359-363, 1997.
5. Boden G, Cheung P, Stein TP, Kresge K, Mozzoli M. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am J Physiol. Endocrinol. Metab, 283: E12-E19, 2002.
6. Hawkins M, Barzilai N, Liu R, Hu M, Chen W, Rossetti L. Role of the glycosamine pathway in fat-induced insulin resistance. J. Clin. Invest, 99(9): 2173-2182, 1997.
7. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, et al. Effects of free fatty acids on glucose transport and IRS-1 associated phosphatidylinositol 3-kinase activity. J Clin. Invest, 103: 253-259, 1999.
8. Chapman MJ. How does nicotinic acid modify the lipid profile? Eur. Heart J Suppl, Supplement F: F54-F59, 2006.
9. Daniels S, Clark F, Spivey R, Golf M, Diamond E, Robson M, et.al. Acurox™ (oxycodone HCl/Niacin) tablets for the treatment of acute moderate to severe pain following bunionectomy surgery in adult patients. J. Pain, 10(4): S34, 2009.
10. Rodriguez-Moran M, Guerrero-Romero F. Oral Magnesium supplrementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects. Diabetes Care, 26(4): 1147-1152, 2003.
11. Suarez A, Pulido N, Casla A, Casanova B, Arrieta FJ, Rovira A. Impaired tyrosine-kinase activity of muscle insulin receptors from hypomagnesaemic rats. Diabetologia, 38(11): 1262-1270, 1995.
12. Infante RB, Garcia OE, Carmona A, Rivera CJ. Effect of legume dietary fiber on rate dissaccharisase activity in vitro. Nutr. Food Sci, 38(4): 316-324, 2008.
13. Landin K, Holm G, Tengborn L, Smith U. Guar gum improves insulin sensitivity, blood lipids, blood pressure and fibrinolysis in healthy men. Am J Clin. Nutr, 56: 1061-1065, 1992.
14. Liang F, Kume S, Koya D. SIRT1 and insulin resistance. Nature Rev. Endocrinol, 5: 367-373, 2009.
15. Larner J. D-Chiro-Insositol - Its functional role in Insulin Action and its Defect in Insulin Resistance. Int. J Exp. Diab. Res, 3: 47-60, 2002.
16. Burger JL, Cape SP, Braun CS, McAdams DH, Best JA, Bhagwat P, et. al. Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine. J. Aerosol Med. And Pulmonary drug delivery, 21(1): 25-34, 2008.
17. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature, 440: 944-948, 2006.
18. Manning PJ, DeJong SA, Sutherland WHF, Ryalls AR, Walker RJ, Berry EA, Williams SM. Effect of high-dose vitamin E on insulin resistance and associated parameters in overweight subjects. Diab. Care, 27(9): 2166-2171, 2004.
19. Gao Z, Hwang D, Bataille F, Lefevre M, York D, Quon MJ, Ye J. Serine phosphorylation of Insulin receptor substrate 1 by inhibitor kB kinase complex. J Biol. Chem, 277(50): 48115-48121, 2002.
20. Hennig B, Meeraranai P, Ramadaas P, Watkins BA, Toborek M. Fatty acid-mediated activation of vascular endothelial cells. Metab, 49(8): 1006-1013, 2000.
21. Davidson M H. Mechanism s for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am. J. Cardiol, 98(4): 27-33, 2006.
22. Ogawa N, Satsu H, Watanabe H, Fukaya M, Tsukamoto Y, Miyamoto Y, Shimizu M. Acetic acid suppresses the increase in disaccharidase activity that occurs during culture of Caco-2 cells. J Nutr, 130: 507-513, 2000.
23. White AM, Johnston CS. Vinegar ingestion at bedtime moderates waking glucose concentrations in adults with well controlled type 2 diabetes. Diab. Care, 30(11): 2814-2815, 2007.
24. Brighenti F, Castellani G, Benini L, Casiraghi MC, Leopardi E, Crovetti R, Testolin G. Effects of neutralized and native vinegar on blood glucose and acetate responses to a mixed meal in healthy subjects. Eur. J Clin. Nutr, 49(4): 242-247, 1995.
25. Roglans N, Vila L, Farre M, Alegret M, Sanchez RM, Vazquez-Carrera M, Laguna JC. Impairment of hepatic Stat-3 activation and reduction of PPARá in fructose-fed rats. Hepatol, 45(3): 778-788, 2007.
26. Chakravarthy MV, Lodhi IJ, Yin L, Malapaka RR, Xu H, Turk J, Semenkovich CF. Identification of a physiologically relevant endogenous ligand for PPARá in liver. Cell, 138(3): 476-488, 2009.
27. Korotchkina LG, Sidhu S, Patel MS. R-lipoic acid inhibits mammalian pyruvate dehydrogenase kinase. Free Radic. Res, 38: 1083-1092, 2004.
28. Nemeth ZH, Bleich D, Csoka B, Pacher P, Mabley JG, Himer L, et.al. Adenosine receptor activation ameliorates type 1 diabetes. FASEB J, 21: 2379-2388, 2007.
29. CANFITE Biopharma Ltd. Press release July 24, 2007. "Preclinical studies demonstrate that the excipients used in the placebo and CF101 drug enhanced the anti-inflammatory effect of methotrexate (MTX)"
30. Eckel RH, Hanson AS, Chen AY, Berman JN, Yost TJ, Brass EP. Dietary substitution of medium chain triglycerides improves insulin mediated glucose metabolism in NIDDM subjects, Diabetes, 41(5): 641-647, 1992.
31. Han JR, Deng B, Sun J, Chen CG, Corkey BE, Kirkland JL, Ma J, Guo W. Effects of dietary medium chain triglyceride on weight loss and insulin sensitivity in a group of moderately overweight free living type 2 diabetic Chinese subjects. Metab. Clin. Exp, 56: 985-991, 2007.
32. Mencher SK, Wang LG. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clinical Pharmacol, 5: 3, 2005.
33. Ribnicky DM, Kuhn P, Poulev A, Logendra S, Zuberi A, Cefalu WT, Raskin I. Improved absorption and bioactivity of active compounds from an anti-diabetic extract of Artemisia dracunculus L. Int. J. Pharmaceutics, 370: 87-92, 2009.
34. Apte SP, Ugwu SU. Emerging excipients in parenteral medications: The new paradigm. In Katdare A, Chaubal MV (eds), Excipient development for Pharmaceutical Biotechnology and Drug Delivery Systems. Informa Healthcare USA, Inc. New York, NY, pp: 357-372, 2006.
35. Fialho AM, DasGupta TK, Chakrabarty AM. Designing promiscuous drugs? Look what nature made! Drug Design and Discovery, 4: 40-43, 2007.
36. Wwllen KE, Hotamisligil GS. Inflammation, stress and diabetes. J. Clin. Invest, 115(5): 1111-1119, 2005.
37. Paolisso G, D'Amore A, Giugliano D, Ceriello A, Varricchio M, D'Onofrio F. Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin-dependent diabetic patients. Am.J. Clin. Nutr, 57: 650-656, 1993.
38. Knopp RH. Evaluating niacin in its various forms. Am.J.Cardiol, 86(suppl): 51L-56L, 2000.
39. Rodriguez-Moran M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects. Diabetes Care, 26: 1147-1152, 2003.
40. Figueiredo MSO, Alfenas RCG, Franceschini SCC, Peluzio MCG, Azeredo RM, Ribeiro SMR. Effect of guar gum supplementation on lipidic and glycidic metabolic control and body mass index in type 2 diabetes. Rev. Nutr. Campinas, 19(2): 187-194, 2006.
41. Gannon MC, Nuttall JA, Nuttall FQ. Oral arginine does not stimulate an increase in insulin concentration but delays glucose disposal. Am.J.Clin.Nutr, 76: 1016-1022, 2002.
42. Maki KC, Van Elswyk ME, McCarthy D, Hess SP, Veith PE, Bell M, Suhhaiah P, Davidson MH. Lipid responses to a dietary docosahexaenoic acid
43. supplement in men and women with below average levels of high density lipoprotein cholesterol. J. Am. Coll. Nutr, 24(3): 189-199, 2005.
44. Jacob S, Ruus P, Hermann R, Tritschler HJ, Maerker E, Renn W, Augustin HJ, Dietze J, Rett K. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo controlled pilot trial. Free Radic. Biol. Med, 27(3-4): 309-314, 1999.